======= C9orf41 ======= == Gene Information == * **Official Symbol**: CARNMT1 * **Official Name**: carnosine N-methyltransferase 1 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=138199|138199]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q8N4J0|Q8N4J0]] * **Interactions**: [[https://thebiogrid.org/search.php?search=C9orf41&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20C9orf41|Open PubMed]] * **OMIM**: [[https://omim.org/entry/616552|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: N-methyltransferase that mediates the formation of anserine (beta-alanyl-N(Pi)-methyl-L-histidine) from carnosine. Anserine, a methylated derivative of carnosine (beta-alanyl-L- histidine), is an abundant constituent of vertebrate skeletal muscles. Also methylates other L-histidine-containing di- and tripeptides such as Gly-Gly-His, Gly-His and homocarnosine (GABA- His). {ECO:0000269|PubMed:26001783}. |N2227| |carnosine N-methyltransferase activity| |carnosine metabolic process| |histidine catabolic process| |imidazole-containing compound catabolic process| |histidine metabolic process| |S-adenosylmethionine-dependent methyltransferase activity| |imidazole-containing compound metabolic process| |aromatic amino acid family catabolic process| |aromatic amino acid family metabolic process| |alpha-amino acid catabolic process| |cellular amino acid catabolic process| |cellular modified amino acid metabolic process| |alpha-amino acid metabolic process| |carboxylic acid catabolic process| |organic acid catabolic process| |cellular amino acid metabolic process| |methylation| |heterocycle catabolic process| |cellular nitrogen compound catabolic process| |small molecule catabolic process| |aromatic compound catabolic process| |organic cyclic compound catabolic process| |drug metabolic process| |peptide metabolic process| |cellular amide metabolic process| |carboxylic acid metabolic process| |oxoacid metabolic process| |organic acid metabolic process| |organonitrogen compound catabolic process| |small molecule metabolic process| |organic substance catabolic process| |cellular catabolic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp485|GSK626616 14μM R08 exp485]]|-2.51| |[[:results:exp116|AICAR 240μM R03 exp116]]|-2.2| |[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-1.85| |[[:results:exp517|Quercetin 20μM R08 exp517]]|-1.85| |[[:results:exp460|BML-284 0.09μM R08 exp460]]|-1.83| |[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-1.83| |[[:results:exp374|Latrunculin-B 10μM R07 exp374]]|-1.7| |[[:results:exp146|Quinacrine 2.5μM R03 exp146]]|1.73| |[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.87| |[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|1.94| |[[:results:exp198|Etoposide 0.1μM R05 exp198]]|2.11| |[[:results:exp301|VER-155008 3.9μM R06 exp301]]|2.2| |[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|2.26| |[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|2.29| |[[:results:exp282|Fluvastatin 2.2μM R06 exp282]]|2.71| |[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|3.64| |[[:results:exp264|Arsenate 40μM R06 exp264]]|3.9| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 2169 * **Expression level (log2 read counts)**: 5.46 {{:chemogenomics:nalm6 dist.png?nolink |}}